N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide

• ChemBase ID: 72511
• Molecular Formular: C29H31N5O4
• Molecular Mass: 513.58754
• Monoisotopic Mass: 513.2376045
• SMILES: O1CCN(CC1)CCCOc1c(cc2c(c1)ncnc2Nc1ccc(cc1)NC(=O)c1ccccc1)OC
• Canonical SMILES: COc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(cc1)NC(=O)c1ccccc1
• InChI: InChI=1S/C29H31N5O4/c1-36-26-18-24-25(19-27(26)38-15-5-12-34-13-16-37-17-14-34)30-20-31-28(24)32-22-8-10-23(11-9-22)33-29(35)21-6-3-2-4-7-21/h2-4,6-11,18-20H,5,12-17H2,1H3,(H,33,35)(H,30,31,32)
• InChIKey: OGNYUTNQZVRGMN-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide
• IUPAC Traditional name: N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide
• Synonyms: ZM-447439; N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide; ZM 447439

Database IDs

• CAS Number: 331771-20-1
• PubChem SID: 162037436
• PubChem CID: 9914412

CALCULATED PROPERTIES

• Acid pKa: 12.41361
• H Acceptors: 8
• H Donor: 2
• LogD (pH = 5.5): 2.71315
• LogD (pH = 7.4): 3.992676
• Log P: 4.0960917
• Molar Refractivity: 148.0191 cm^3
• Polarizability: 56.95799 Å^3
• Polar Surface Area: 97.84 Å^2
• Rotatable Bonds: 10
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: DMSO
• Apperance: Pale Yellow Solid
• Melting Point: 117-120°C

Safety Information

• Storage Condition: -20°C; Refrigerator

Pharmacology Properties

• Target: Aurora Kinase

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S1103

Research Area

• Description: Canccer

Biological Activity

• Description: ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively.
• Targets: Aurora A; Aurora B
• IC50: 110 nM; 130 nM ^[1]
• In Vitro: In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. ^[1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G₀ /G₁and G₂/M phase of the cell cycle. ^[2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. ^[3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. ^[4]
• Features: ZM-447439 is an Aurora selective ATP-competitive inhibitor.

Protocol

• Protocol: Kinase Assay ^[1]
• In vitro kinase assays: Recombinant Aurora A and B are expressed as NH₂-terminal His₆-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl₂, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[^33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of ^33P with a Betaplate^TM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.
• Protocol: Cell Assay ^[2]
• Cell Lines: BON, QGP-1 and MIP-101 cells
• Concentrations: 0-5 μM
• Incubation Time: 72 hours
• Methods: Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.

References

• References: [1] Ditchfield C, et al. J Cell Biol. 2003, 161(2), 267-280.
• References: [2] Georgieva I, et al. Neuroendocrinology. 2010, 91(2), 121-130.
• References: [3] Teperek-Tkacz M, et al. Cell Cycle. 2010, 9(23), 4674-4687.
• References: [4] Zhang L, et al. J Obstet Gynaecol Res. 2011, 37(6), 591-600.

Toronto Research Chemicals - Z487000

It is a potent and selective inhibitor of Aurora B kinase. Cells treated with ZM-447439 progress through interphase, enter mitosis and assemble bipolar spindles but chromosome alignment, segregation and cytokinesis all fail. It induces apoptosos in Hep2 c

REFERENCES

• Ditchfield C, et al. J Cell Biol. 2003, 161(2), 267-280.
• Teperek-Tkacz M, et al. Cell Cycle. 2010, 9(23), 4674-4687.
• Georgieva I, et al. Neuroendocrinology. 2010, 91(2), 121-130.
• Zhang L, et al. J Obstet Gynaecol Res. 2011, 37(6), 591-600.
• Ditchfield, C., et al.: J. Cell Biol., 161, 267 (2003)
• Long, Z.J., et al.: J. Cell Cycle, 7, 1473 (2003)
• Walsby, E., et al.: Haematologica, 93, 662 (2003)